Vaxcyte Is Maintained at Outperform by Mizuho
Vaxcyte Analyst Ratings
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $130
A Quick Look at Today's Ratings for Vaxcyte(PCVX.US), With a Forecast Between $113 to $160
Vaxcyte Is Maintained at Buy by B of A Securities
Vaxcyte's VAX-31 Vaccine Poised to Dominate PCV Market: A Comprehensive Buy Rating Analysis
Vaxcyte Analyst Ratings
Vaxcyte's V AX-31 Demonstrates Market Disruption Potential With Strong Clinical Trial Results; Buy Rating Reaffirmed With Increased Price Target
Buy Rating Affirmed for Vaxcyte Amidst Strong Growth Potential and Competitive Market Position
Vaxcyte Analyst Ratings
Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
Optimistic Buy Rating for Vaxcyte Amidst Promising Vaccine Candidate Progress and Strategic Positioning
Jefferies Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $108
Strong Buy Rating for Vaxcyte as VAX-31 Poised to Capture Significant PCV Market Share
Jefferies Keeps Their Buy Rating on Vaxcyte (PCVX)
TD Cowen Remains a Buy on Vaxcyte (PCVX)
Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target